

Applicants : Moses Rodriguez and Daren Ure
U.S. Serial No.: Not Yet Known (Divisional application of
U.S. Serial No. 09/885,227)
Filed : Herewith
Page 8

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §1.97(b)(1)

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following publications which are listed again on the attached Form PTO-1449 (**Exhibit A**). Copies of References 6 and 7 are attached hereto as **Exhibits 1** and **2**.

This Information Disclosure Statement is being submitted within three months of the filing date of the subject application. Pursuant to 37 C.F.R. § 1.97(b)(1), no fee is required for filing this Information Disclosure Statement.

1. U.S. Patent No. 5,591,629, issued January 7, 1997 (Rodriguez et al.).
2. U.S. Patent No. 5,800,808, issued September 1, 1998 (Konfino et al.).
3. U.S. Patent No. 5,981,589, issued November 9, 1999 (Konfino et al.).
4. U.S. Patent No. 6,048,898, issued April 11, 2000 (Konfino et al.).
5. U.S. Patent No. 6,054,430, issued April 25, 2000 (Konfino et al.).
6. U.S. Patent Publication No. 20020182210 A1, published December 5, 2002 (Rodriguez, et al.), Issue fee paid February 2, 2004, not yet issued, (**Exhibit 1**).

Applicants : Moses Rodriguez and Daren Ure
U.S. Serial No.: Not Yet Known (Divisional application of
U.S. Serial No. 09/885,227)
Filed : Herewith
Page 9

7. Allowed claims of U.S. Serial No. 09/885,227 (Rodriguez, et al.), U.S. Patent Publication No. 20020182210 A1, for the Examiner's convenience, (**Exhibit 2**).
8. WO 00/05250, published February 3, 2000 (Aharoni et al.).
9. Ben-Nun, A. et al. 1996. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of Copolymer 1 on MOG-induced disease. J. Neurol. 243(Suppl 1): S14-S22.
10. Fridkis-Hareli, et al., "Direct Binding of Myelin Basic Protein and Synthetic Copolymer 1 to Class II Major Histocompatibility Complex Molecules on Living Antigen-Presenting Cells - Specificity and Promiscuity", Proc. Natl. Acad. Sci. USA, 1994, 91: 4872-4876.
11. Lisak, R.P. et al. 1983. Effect of treatment with Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of Experimental Allergic Encephalomyelitis (EAE). J. Neurol. Sci. 62: 281-293.
12. Pavelko, K.D., B.G. van Engelen and M. Rodriguez. 1998. Acceleration in the rate of CNS remyelination in lysolecithin-induced demyelination. J. Neurosci. 18: 2498-2505.
13. Puri et al., "Modulation of the Immune Response in Multiple Sclerosis", J. Immunol., 1997, 158: 2471-2476.
14. Sela, M. et al. 1990. Suppressive activity of Cop-1 in

Applicants : Moses Rodriquez and Daren Ure
U.S. Serial No.: Not Yet Known (Divisional application of
U.S. Serial No. 09/885,227)
Filed : Herewith
Page 10

EAE and its relevance to multiple sclerosis. Bull. Inst.
Pasteur. 88:303-314.

15. Teitelbaum, D., A. Meshorer, T. Hirshfeld, R. Arnon and M. Sela. 1971. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1: 242-248.
16. Teitelbaum, D., C. Webb, A. Meshorer, R. Arnon and M. Sela. 1973. Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. Eur. J. Immunol. 3: 273-279.
17. Teitelbaum, D. et al. 1996. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J. Neuroimmunol. 64: 209-217.
18. Teitelbaum, D., R. Aharoni, M. Sela and R. Arnon. 1991. Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic Copolymer 1. Proc. Natl. Acad. Sci. USA 88:9528-9532.
19. Webb, C. et al. 1973. In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing Experimental Allergic Encephalomyelitis, Eur. J. Immunol. 3: 279-286.

Applicants : Moses Rodriquez and Daren Ure
U.S. Serial No.: Not Yet Known (Divisional application of
U.S. Serial No. 09/885,227)
Filed : Herewith
Page 11

The subject application is a divisional of and claims the benefit under 35 U.S.C. §120 of U. S. Serial No. 09/885,227, filed June 20, 2001. The above listed references 1-5, 8-11 and 13-19 were submitted in an Information Disclosure Statement filed on October 18, 2002 in connection with U.S. Serial No. 09/885,227. The above listed reference 12 was submitted in a Supplemental Information Disclosure Statements filed on October 18, 2002 in connection with U.S. Serial No. 09/885,227. Copies of listed references 6 and 7 are attached hereto.

Pursuant to 37 C.F.R. §1.98(d) copies of listed references 1-5 and 8-19 are not provided to the United States Patent and Trademark Office, because they were previously submitted or cited in an application relied upon for an earlier filing date under 35 U.S.C. §120.


Applicants : Moses Rodriguez and Daren Ure
U.S. Serial No.: Not Yet Known (Divisional application of
U.S. Serial No. 09/885,227)
Filed : Herewith
Page 12

Applicants request that the Examiner review the publications and make them of record in the subject application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee, other than the enclosed \$964.00 filing fee, is deemed necessary in connection with the filing of this Preliminary Amendment and Information Disclosure Statement. A check in that amount is enclosed herewith. However, if any additional fee is required, authorization is hereby give to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,


John P. White
Registration No. 28,678
Gary J. Gershik
Registration No. 39,992
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
Tel (212) 278-0400

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office				Atty. Docket No. 60726-AZ/JPW/GJG/DJK		Serial No. Not yet known	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)						Applicants: Moses Rodriguez and Daren Ure			
						Filing Date herewith		Group Art Unit	

U.S. PATENT DOCUMENTS														
Examiner Initial	Exhibit No.	Document Number								Date	Name	Class	Subclass	Filing Date if Appropriate
		5	5	9	1	6	2	9	1/7/1997	Rodriguez, et al.				
		5	8	0	0	8	0	8	9/1/1998	Konfino, et al.				
		5	9	8	1	5	8	9	11/9/1999	Konfino, et al.				
		6	0	4	8	8	9	8	4/11/2000	Konfino, et al.				
		6	0	5	4	4	3	0	4/25/2000	Konfino, et al.				
	1	20	02	01	82	2	1	0	12/5/2002	Rodriguez, et al.				

FOREIGN PATENT DOCUMENTS																
		Document Number								Date	Country	Class	Subclass	Translation		
		Yes		No												
		WO	00	0	5	2	5	0	2/3/2000							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
2	Allowed claims of U.S. Serial No. 09/885,227 (Rodriguez, et al.), U.S. Patent Publication No. 20020182210 A1, for the Examiner's convenience.
	Ben-Nun, A. et al. 1996. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of Copolymer 1 on MOG-induced disease. J. Neurol. 243(Suppl 1): S14-S22.
	Fridkis-Hareli, et al., "Direct Binding of Myelin Basic Protein and Synthetic Copolymer 1 to Class II Major Histocompatibility Complex Molecules on Living Antigen-Presenting Cells - Specificity and Promiscuity", Proc. Natl. Acad. Sci. USA, 1994, 91: 4872-4876.
	Lisak, R.P. et al. 1983. Effect of treatment with Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of Experimental Allergic Encephalomyelitis (EAE). J. Neurol. Sci. 62: 281-293.

EXAMINER	DATE CONSIDERED
-----------------	------------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AA/JPW/ GJG/DJK		Serial No. Not yet known				
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicants: Moses Rodriguez and Daren Ure						
					Filing Date herewith		Group Art Unit				
U.S. PATENT DOCUMENTS											
Examiner Initial	Exhibit No.	Document Number				Date	Name	Class	Subclass	Filing Date if Appropriate	
FOREIGN PATENT DOCUMENTS											
		Document Number				Date	Country	Class	Subclass	Translation	
										Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
		Pavelko, K.D., B.G. van Engelen and M. Rodriguez. 1998. Acceleration in the rate of CNS remyelination in lysolecithin-induced demyelination. J. Neurosci. 18: 2498-2505.									
		Puri et al., "Modulation of the Immune Response in Multiple Sclerosis", J. Immunol., 1997, 158: 2471-2476.									
		Sela, M. et al. 1990. Suppressive activity of Cop-I in EAE and its relevance to multiple sclerosis. Bull. Inst. Pasteur. 88:303-314.									
		Teitelbaum, D., A. Meshorer, T. Hirshfeld, R. Arnon and M. Sela. 1971. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1: 242-248.									
		Teitelbaum, D., C. Webb, A. Meshorer, R. Arnon and M. Sela. 1973. Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. Eur. J. Immunol. 3: 273-279.									
		Teitelbaum, D. et al. 1996. Copolymer I inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J. Neuroimmunol. 64: 209-217.									
		Teitelbaum, D., R. Aharoni, M. Sela and R. Arnon. 1991. Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic Copolymer I. Proc. Natl. Acad. Sci. USA 88:9528-9532.									
		Webb, C. et al. 1973. In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing Experimental Allergic Encephalomyelitis, Eur. J. Immunol. 3: 279-286.									
EXAMINER				DATE CONSIDERED							
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											